🍽️ troglitazone,(prescription)

Type 2 Diabetes Mellitus:

• Glucose Control: Troglitazone belongs to a class of medications known as thiazolidinediones (TZDs) or glitazones. It works by increasing the sensitivity of the body's cells to insulin, thereby improving glucose utilization and reducing blood sugar levels in patients with type 2 diabetes mellitus.

Insulin Sensitization:

• Improvement of Insulin Resistance: Troglitazone targets insulin resistance, a key feature of type 2 diabetes mellitus, by activating peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue, skeletal muscle, and the liver. This action enhances insulin-mediated glucose uptake and utilization in these tissues.

Management of Lipid Abnormalities:

• Lipid Profile Improvement: Troglitazone has been shown to have favorable effects on lipid metabolism, leading to reductions in triglycerides and increases in high-density lipoprotein (HDL) cholesterol levels in some patients with type 2 diabetes.

Non-Alcoholic Fatty Liver Disease (NAFLD):

• Hepatic Steatosis: Troglitazone was also investigated for its potential benefit in the treatment of non-alcoholic fatty liver disease (NAFLD) due to its ability to reduce hepatic fat accumulation. However, its use in this condition is limited by safety concerns.

Adverse Effects:

• Hepatotoxicity: Troglitazone was withdrawn from the market due to reports of severe hepatotoxicity, including cases of liver failure and death. The risk of liver injury associated with troglitazone led to its removal from the market and discontinuation of its use in clinical practice.
• Fluid Retention: Like other TZDs, troglitazone can cause fluid retention, which may manifest as peripheral edema or exacerbation of heart failure symptoms in susceptible individuals.